INSOMNIA IN ALZHEIMER DISEASE: MOVING TOWARD SAFER, MORE EFFECTIVE SLEEP SOLUTIONS

Released On
December 31, 2019

Expires On
December 31, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Geriatric, Primary Care

Topic(s)
Alzheimers Disease

Scroll to the Bottom of this Information to Begin this Course

This activity is jointly provided by Postgraduate Institute for Medicine and MedEdicus LLC.

 

Supported by an independent educational grant from Merck & Co., Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

Primary Care Physicians, Nurse Practitioners, and Physician Assistants in Geriatric Practice

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the consequences of untreated insomnia in AD
  • Describe the bidirectional relationship between sleep disturbances and neurocognitive disorders
  • Integrate insomnia assessment into routine encounters with patients with AD
  • Review clinical trial data for emerging therapies for insomnia in AD
  • Develop comprehensive and safe management strategies for patients with insomnia and AD

Faculty

Alon Y. Avidan, MD, MPH, HAAN, FAASM

Professor and Vice Chair
Department of Neurology
David Geffen School of Medicine
Director
Sleep Disorders Center
University of California, Los Angeles
Los Angeles, California

Larry Culpepper, MD, MPH

Professor of Family Medicine
Department of Family Medicine
Boston University School of Medicine
Boston, Massachusetts

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MedEdicus LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Continuing Nursing Education The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Disclosures of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Alon Y. Avidan, MD, MPH, HAAN, FAASM

  • Consulting fees: Eisai Inc; Harmony Biosciences, LLC; and Merck & Co., Inc
  • Data and Safety Monitoring funding: Balance Therapeutics; and Merck & Co., Inc

Larry Culpepper, MD, MPH

  • Consulting fees: Acadia Pharmaceuticals, Inc; Allergan; Eisai Inc; Merck & Co., Inc; Supernus Pharmaceuticals, Inc; and Takeda Pharmaceuticals USA, Inc
  • Ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds) in M-3 Information, LLC

Planners and Managers
The PIM planners and managers have nothing to disclose. The MedEdicus planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Method of Participation and Request for Credit

There are no fees for participating in and receiving CME/CE credit for this activity. During the period December 20, 2019, through December 20, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, a certificate will be made available immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

© 2019 MedEdicus LLC